Related references
Note: Only part of the references are listed.The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
N. J. Ashton et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Alzheimer's disease
Philip Scheltens et al.
LANCET (2021)
Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics
Henrik Zetterberg et al.
MOLECULAR NEURODEGENERATION (2021)
Parkinson's disease
Bastiaan R. Bloem et al.
LANCET (2021)
Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population-Based 10-Year Study
Kathrin Marini et al.
MOVEMENT DISORDERS (2021)
Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders
Isabel Schulz et al.
MOVEMENT DISORDERS (2021)
Influence of individual, illness and environmental factors on place of death among people with neurodegenerative diseases: a retrospective, observational, comparative cohort study
Richard Nicholas et al.
BMJ SUPPORTIVE & PALLIATIVE CARE (2021)
Blood biomarkers with Parkinson's disease clusters and prognosis: the oxford discovery cohort
Michael Lawton et al.
MOVEMENT DISORDERS (2020)
An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead
Joel Simren et al.
CURRENT OPINION IN NEUROBIOLOGY (2020)
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression
Brit Mollenhauer et al.
MOVEMENT DISORDERS (2020)
The good, the bad, and the opportunities of the complement system in neurodegenerative disease
Nicole D. Schartz et al.
JOURNAL OF NEUROINFLAMMATION (2020)
CSF and blood biomarkers for Parkinson's disease
Lucilla Parnetti et al.
LANCET NEUROLOGY (2019)
Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
Liu Shi et al.
ALZHEIMERS & DEMENTIA (2019)
Characterization of Parkinson's disease using blood-based biomarkers: A multicohort proteomic analysis
Marijan Posavi et al.
PLOS MEDICINE (2019)
Complement in the pathogenesis of Alzheimer's disease
B. Paul Morgan
SEMINARS IN IMMUNOPATHOLOGY (2018)
A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease
Nicholas T. Seyfried et al.
CELL SYSTEMS (2017)
The Parkinson's Disease-Associated Protein Kinase LRRK2 Modulates Notch Signaling through the Endosomal Pathway
Yuzuru Imai et al.
PLOS GENETICS (2015)
The Prevalence of Parkinson's Disease: A Systematic Review and Meta-analysis
Tamara Pringsheim et al.
MOVEMENT DISORDERS (2014)
The influence of age and gender on motor and non-motor features of early Parkinson's disease: Initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort
Konrad Szewczyk-Krolikowski et al.
PARKINSONISM & RELATED DISORDERS (2014)
Plasma Apolipoprotein A1 as a Biomarker for Parkinson Disease
Judy K. Qiang et al.
ANNALS OF NEUROLOGY (2013)
Axon degeneration in Parkinson's disease
Robert E. Burke et al.
EXPERIMENTAL NEUROLOGY (2013)
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Guangchuang Yu et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2012)
Plasma Epidermal Growth Factor Levels Predict Cognitive Decline in Parkinson Disease
Alice S. Chen-Plotkin et al.
ANNALS OF NEUROLOGY (2011)
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Larry Gold et al.
PLOS ONE (2010)
WGCNA: an R package for weighted correlation network analysis
Peter Langfelder et al.
BMC BIOINFORMATICS (2008)
Adjusting batch effects in microarray expression data using empirical Bayes methods
W. Evan Johnson et al.
BIOSTATISTICS (2007)
Proteome analysis of human substantia nigra in Parkinson's disease
M Basso et al.
PROTEOMICS (2004)
The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service
AJ Hughes et al.
BRAIN (2002)